Preview

Obstetrics, Gynecology and Reproduction

Advanced search

SOME OF SEROLOGICAL MARKERS DURING PELVIC PAIN CAUSED BY ADENOMYOSIS

Full Text:

Abstract

One of the dominant clinical symptoms of adenomyosis is chronic pelvic pain . Chronic pelvic pain is recurrent or persistent pain that bothers patient less than 6 months. The aim of the study was to determine the clinical informativeness use of oncological markers CA-125 and NOT-4 in blood serum of women with pelvic pain caused by
adenomyosis. In the present study included 63 patients adenomyosis – as a core group, and 30 apparently healthy women of reproductive age as a comparison group. Indicators CA-125 were higher in patients in the second subgroup with moderately severe pain syndrome, and the average at the time of treatment amounted to 45-63 U/ml, P<0.001), but on the second day of the menstrual cycle indicators again increased and averaged 54-70 U/ml ,and also significantly (P<0.001) decreased in the study after the end of the regular menstruation( 1st-2nd dry day after menstruation in the framework of the first phase of the menstrual cycle and averaged 42-60 U/ml compared with the comparison group apparently healthy women-8.9 IU/ml Conclusion , the evidence suggests that women with pelvic pain syndrome adenomyosis is the place to co-proliferative endometrial pathology. And in these cases increasyse the sensitivity of the above serological markers. The use of two markers (NOT-4 and CA-125) has a more accurate diagnostic value to identify the process of malignization in the reproductive organs, and it is important for differential diagnosis of hyperplastic processes, and for early diagnosis of endometrial adenocarcinoma.

About the Author

M. R. Orazov
Research Institute of medical family problems Donetsk national medical University named M. Gorky (Ukraine)
Ukraine


References

1. Адамян Л.В. Генитальный эндометриоз: клиника, диагностика, лечение: метод. Рекомендации. М. 1997; 31 с.

2. Адамян Л.В. Эндометриозы: руководство для врачей. М. 1998; 320 с.

3. Адамян Л.В., Яроцкая Е.Л. Генитальный эндометриоз: дискуссионные вопросы и альтернативные подходы к диагностике и лечению. Журнал акушерства и женских болезней. 2002; 2: 103.

4. Ахмедова С.А. Совершенствование клинико-лабораторной концепции использования СА-125 у больных раком яичников: автореф. дис. ... канд. биол. наук. М., 2003.

5. Баранов B.C. Геном человека и гены «предрасположенности» / B.C. Баранов, Е.В.Баранова, Ж.Э. Иващенко, М. Асеев. СПб. 2000; 272 с.

6. Баскаков В.И. Эндометриоз на современном этапе. 2001; 14-15.

7. Дамиров М.М. Аденомиоз: клиника, диагностика и лечение. Москва – Тверь. 2002; 294 с.

8. Новикова Е.Г., Ронина Е.А. Некоторые эпидемиологические показатели и диагностика злокачественных опухолей яичников. Материалы пленума проблемной комиссии 01.04 «Диагностика и лечение гинекологических заболеваний». Иркутск. 1998; 111-117.

9. Сергеева Н.С., Ермошина Н.В., Мишунина М.П. и др. Использование опухолеассоциированных маркеров для диагностики и контроля эффективности терапии у больных с распространенным раком яичников. М. 2002.

10. Чернуха. Г.Е. Эндометриоз и хроническая тазовая боль: причины и последствия. Проблемы репродукции. 2011; 5: 83-86.

11. Drapkin R., von Horsten H., Lin Y., Mok S., Crum C., Welch W., Hecht J. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162-2169.

12. Havrilesky L., Whitehead C., Rubatt J., Cheek R., Groelke J., He Q., Malinowski D., Fischer T., Berchuck A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 2008; 110: 374-382.

13. Moore R., Brown A., Miller M., Badgwell D., Lu Z., Allard W., Granai C., Bast R.J., Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008b; 110: 196-201.

14. Nagle C.M., Webb P.M. The influence of reproductive and hormonal factors on ovarian cancer survival. Int. J. Gynecol. 2008; 18: 407-413.

15. Ness R.B., Serologic Evidence of Past Infection with Chlamidiya trahomatis, in Relation to ovarian Cancer. Journal of Infectious Diseases. 2003; 187: 1147-1152.

16. Markman M. Randomized phase 3 study of intravenous (IV) cisplatin (CIS) and intraperitoneal (IP) CIS in optimal residual ovarian cancer. Clinic oncology. 1998; 17: 361-367.

17. Terry K., Sluss P. Blood and urine markers for ovarian cancer a comprehensive review. Dis. Markers. 2004; 20: 53-70.

18. Hellström I. et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer. Research. 2003; 63: 3695-3700.


For citation:


Orazov M.R. SOME OF SEROLOGICAL MARKERS DURING PELVIC PAIN CAUSED BY ADENOMYOSIS. Obstetrics, Gynecology and Reproduction. 2013;7(4):6-10. (In Russ.)

Views: 180


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)